@article{andre:hal-03975142,
TITLE = {Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study},
AUTHOR = {Andr{\'e},
T. and Tougeron, D and Piessen, G. and de La Fouchardi{\`e}re, C and Louvet, C and Adenis, A. and Jary, M. and Tournigand, C and Aparicio, T. and Desrame, J. and Lievre, A. and Garcia-Larnicol, M.-L. and Pudlarz, T. and Cohen, R. and Memmi, S. and Vernerey, D. and Henriques, J. and Lefevre, J. H. and Svrcek, M},
URL = {https://hal.science/hal-03975142},
JOURNAL = {Journal of Clinical Oncology},
PUBLISHER = {American Society of Clinical Oncology},
VOLUME = {41},
NUMBER = {2},
PAGES = {255-265},
YEAR = {2023},
MONTH = Jan, DOI = {10.1200/JCO.22.00686},
KEYWORDS = {antineoplastic agent ; ipilimumab ; nivolumab ; adenocarcinoma ; aged ; clinical trial ; gastroesophageal junction ; genetics ; human ; microsatellite instability ; mismatch repair ; neoadjuvant therapy ; pathology ; phase 2 clinical trial ; stomach tumor ; tumor recurrence ; Adenocarcinoma ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; DNA Mismatch Repair ; Esophagogastric Junction ; Humans ; Ipilimumab ; Microsatellite Instability ; Neoadjuvant Therapy ; Neoplasm Recurrence, Local ; Nivolumab ; Stomach Neoplasms},
HAL_ID = {hal-03975142},
HAL_VERSION = {v1},
}
Affichage BibTex